David Haas, MD

David Haas, MD, is Professor of Medicine in the Division of Infectious Diseases at Vanderbilt, and a board-certified infectious diseases specialist. He is an accomplished HIV clinical trialist and leader in human pharmacogenomic research relevant to HIV infection and its therapy, and more recently pharmacogenomics of anti-tuberculosis therapy. He established and has led the AIDS Clinical Trials Group (ACTG) Clinical Research Site at Vanderbilt since its inception. He is co-principal investigator of a multidisciplinary NIH grant entitled "Pharmacogenomics of HIV Therapy," and is highly engaged in multidisciplinary research with an emphasis on the importance of human genomics for antiretroviral and anti-tuberculosis drug disposition, efficacy, and toxicity. He also co-directs the Tennessee Center for AIDS Research.